Page 1 | Search Results | Blood Advances | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

Mehdi Hamadani, Alexander Spira, Xiaolei Zhou, Laura Liao, Lei Chen, John Radford, Weiyun Ai, Melhem Solh, Kirit M. Ardeshna, Brian Hess, Paolo F. Caimi, Anastasios Stathis, Carmelo Carlo-Stella, Juan Pablo Alderuccio, Brad Kahl, Ying Wang, Yajuan Qin, Zhiying Cindy Xu, Pier Luigi Zinzani

Blood Adv (2023) 8 (1): 93–98.

https://doi.org/10.1182/bloodadvances.2023010636

Published: 2023

Includes: Supplemental data

Journal Articles

Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

Juan P. Alderuccio, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Matthew A. Lunning, Brian T. Hess, Pier L. Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Mehdi Hamadani, Brad S. Kahl, David Ungar, Turk Kilavuz, Eric Yu, Yajuan Qin, Paolo F. Caimi

Blood Adv (2022) 6 (16): 4736–4739.

https://doi.org/10.1182/bloodadvances.2022007782

Published: 2022

Journal Articles

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

Bicky Thapa, Paolo F. Caimi, Kirit M. Ardeshna, Melhem Solh, Carmelo Carlo-Stella, Brad S. Kahl, Mehdi Hamadani

Blood Adv (2020) 4 (16): 3850–3852.

https://doi.org/10.1182/bloodadvances.2020002587

Published: 2020